FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

556 letters match. Newest first.

  1. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  2. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  3. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  4. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  5. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  6. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk
  7. Almon Healthcare Private Limited

    Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.

    High risk
  8. BioMylz Pvt. Ltd.

    FDA found destroyed records, inadequate process and cleaning validation, missing microbial testing, and incomplete drug listings at BioMylz, an Indian OTC drug manufacturer.

    High risk
  9. Shimoga Chemicals

    FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.

    High risk
  10. Fareva Amboise

    FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.

    High risk
  11. Spa De Soleil, Inc.

    FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.

    High risk
  12. International Medication Systems Limited

    FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.

    High risk
  13. Excelvision - Fareva

    FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.

    High risk
  14. Wizcure Pharmaa Private Limited

    FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.

    High risk
  15. Yangzhou Hongshengding Chemical Co., Ltd.

    Yangzhou Hongshengding Chemical refused FDA records requests for its over-the-counter drugs, leading to an import alert.

    High risk
  16. Huons Co., Ltd.

    FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.

    High risk
  17. Jubilant HollisterStier General Partnership

    FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

    High risk
  18. Sante Manufacturing Inc.

    Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.

    High risk
  19. Pharmathen International S.A.

    FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.

    High risk
  20. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

    FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

    High risk
  21. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk
  22. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  23. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk
  24. Umendra Life Sciences Private Limited

    Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

    High risk
  25. Erkul Kozmetik Sanayi ve Ticaret A.S.

    Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.

    High risk
  26. PLZ Corp

    FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.

    High risk
  27. Asanuma Corporation - Sagamihara Factory

    FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.

    High risk
  28. Shantou Qiwei Industry Co., LTD

    FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.

    High risk
  29. Zydus Lifesciences Limited

    FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.

    High risk
  30. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  31. Medline Inc

    FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.

    High risk
  32. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk
  33. Aeroflex Industria de Aerosol Ltda.

    Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.

    High risk
  34. Alchymars ICM SM Private Limited

    FDA found Alchymars API manufacturing had poor equipment and facility maintenance, making its APIs adulterated and prompting an import alert.

    High risk
  35. Sato Pharmaceutical Co., Ltd.

    FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

    High risk
  36. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  37. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  38. Hangzhou Yiqi Biotechnology Co., Ltd

    FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.

    High risk
  39. JW Nutritional LLC

    FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.

    High risk
  40. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  41. Naveh Pharma LTD/Bigdam Inc.

    FDA says Naveh Pharma and Bigdam sell unapproved saline drug products in the U.S. and have no quality unit.

    High risk
  42. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk
  43. Active Cosmetics Manufacturing Inc.

    FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.

    High risk
  44. Respilon Production S.R.O.

    FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.

    Medium
  45. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  46. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  47. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  48. Intas Pharmaceuticals Limited

    FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.

    High risk
  49. Par Health USA, LLC & Endo USA, Inc.

    FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.

    High risk
  50. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk